Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Erratum for Stewart et al., J Clin Oncol 27 (11) 1864-1871.

Journal of Clinical Oncology, Vol 27, No 20 (July 10), 2009: pp. 3410
© 2009 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2009.24.4558

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

ERRATA

The April 10, 2009, article by Stewart et al, entitled, "Phase III Study of Gefitinib 250 Compared With Intravenous Methotrexate for Recurrent Squamous Cell Carcinoma of the Head and Neck" (J Clin Oncol 27:1864–1871, 2009), contained errors.

The Title should have read: "Phase III Study of Gefitinib Compared With Intravenous Methotrexate for Recurrent Squamous Cell Carcinoma of the Head and Neck."

In the Patients and Methods section, under Overall Study Design, CTC was defined in the last sentence as Common Toxicity Criteria, whereas it should have been Common Terminology Criteria.

In Table 3, CTC was also defined as Common Toxicity Criteria and should have been Common Terminology Criteria.

In Figure 1, the following footnote was inadvertently omitted: "Evaluable for efficacy, all randomized patients; Evaluable for response, patients with unidimensional measurable disease at baseline as per the Response Evaluation Criteria In Solid Tumors (RECIST) criteria; Evaluable for safety, all patients who received at least 1 dose of study treatment; Evaluable for quality of life, patients with an evaluable baseline quality of life assessment and at least 1 evaluable post-baseline quality of life assessment."

In the legend of Figure 4, parts A and B were mislabeled and should have been: (A) EGFR FISH-positive; (B) EGFR FISH-negative.

In the Contributions section, Ezra E.W. Cohen should have been acknowledged for collection and assembly of data.

The online only Appendix was inadvertently omitted.

The online version has been corrected in departure from the print.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?



This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2009 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online